BMS reports flat revenue growth for full-year 2025
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024. The company's…
All articles by Salong Debbarma
Salong Debbarma
-
-
Apotex and Grünenthal sign deal for Nebido Canadian distribution
Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone undecanoate…
-
Everest Medicines and Micot partner on MT1013 commercialisation
Everest Medicines has signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific (excluding…
-
PrimeGen US and DT Cloud Star sign $1.5bn merger agreement
PrimeGen US and DT Cloud Star Acquisition have entered a definitive business combination agreement at an implied equity value of…
-
Relay Therapeutics’ zovegalisib secures FDA BTD for advanced breast cancer
Relay Therapeutics has received the US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for zovegalisib (RLY-2608), along with…
-
CEPI and Samsung Biologics partner to boost global vaccine preparedness
The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics have partnered in an outbreak-ready vaccine manufacturing partnership to enhance…
-
SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal
SanegeneBio has entered a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its ribonucleic…
-
Aquestive receives FDA CRL for Anaphylm allergic reaction treatment
Aquestive Therapeutics has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its new…
-
CHMP grants positive opinion for J&J’s Akeega use
Johnson & Johnson (J&J) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for…
-
CIRM unveils RAPID funding programme for rare diseases
The California Institute for Regenerative Medicine (CIRM) in the US has approved the Rare Disease Acceleration Platform and Innovation and…